The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
- Sprache
-
Englisch
- Identifier
-
1081555777
Thema
Krebs; Onkologie
Beteiligte Personen und Organisationen
Atmaca, Akin
Werner, Dominique
Pauligk, Claudia
Steinmetz, Kristina
Wirtz, Ralph
Altmannsberger, Hans-Michael
Jäger, Elke
Al-Batran, Salah-Eddin
Werner, Dominique
Pauligk, Claudia
Steinmetz, Kristina
Wirtz, Ralph
Altmannsberger, Hans-Michael
Jäger, Elke
Al-Batran, Salah-Eddin
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:55 MEZ
Beteiligte
- Atmaca, Akin
- Werner, Dominique
- Pauligk, Claudia
- Steinmetz, Kristina
- Wirtz, Ralph
- Altmannsberger, Hans-Michael
- Jäger, Elke
- Al-Batran, Salah-Eddin
Ähnliche Objekte (12)
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
Best practice in gastric cancer and adenocarcinoma of the esophagogastric junction : with 33 tables and 14 therapy protocols
Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC)
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma
Praxis in der Therapie des ösophagogastralen Adenokarzinoms : mit 26 Tabellen sowie 13 Therapieprotokollen
Pharmacogenetics of Extraordinary Responses to 5-FU/Cisplatin Chemotherapy in Advanced Gastric Cancer – Report of 2 Cases
Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma
Wie Checkpoint-Inhibitoren die Therapielandschaft verändern : Immunonkologie bei gastrointestinalen Tumoren
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Biologie und zielgerichtete Therapie des Magenkarzinoms
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms : document summary and in-depth discussion
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
Best practice in gastric cancer and adenocarcinoma of the esophagogastric junction : with 33 tables and 14 therapy protocols
Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC)
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma
Praxis in der Therapie des ösophagogastralen Adenokarzinoms : mit 26 Tabellen sowie 13 Therapieprotokollen
Pharmacogenetics of Extraordinary Responses to 5-FU/Cisplatin Chemotherapy in Advanced Gastric Cancer – Report of 2 Cases
Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma
Wie Checkpoint-Inhibitoren die Therapielandschaft verändern : Immunonkologie bei gastrointestinalen Tumoren
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Biologie und zielgerichtete Therapie des Magenkarzinoms
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms : document summary and in-depth discussion
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
Best practice in gastric cancer and adenocarcinoma of the esophagogastric junction : with 33 tables and 14 therapy protocols
Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC)
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma
Praxis in der Therapie des ösophagogastralen Adenokarzinoms : mit 26 Tabellen sowie 13 Therapieprotokollen
Pharmacogenetics of Extraordinary Responses to 5-FU/Cisplatin Chemotherapy in Advanced Gastric Cancer – Report of 2 Cases
Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma
Wie Checkpoint-Inhibitoren die Therapielandschaft verändern : Immunonkologie bei gastrointestinalen Tumoren
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Biologie und zielgerichtete Therapie des Magenkarzinoms